Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/16142
Título
Effectiveness and tolerability of dolutegravir/lamivudine for the treatment of HIV-1 infection in clinical practice
Autor(es)
Suárez-García, Inés | Alejos, Belén | Hernando Sebastian, Victoria ISCIII | Viñuela, Laura | Vera García, Mar | Rial-Crestelo, David | Pérez Elías, María Jesús | Albendín Iglesias, Helena | Peraire, Joaquim | Tiraboschi, Juan | Diaz Franco, Asuncion ISCIII | Moreno, Santiago | Jarrin-Vera, Inmaculada ISCIII | Spanish HIV/AIDS Research Network (CoRIS)
Fecha de publicación
2023-06-01
Cita
J Antimicrob Chemother. 2023 Jun 1;78(6):1423-1432.
Idioma
Inglés
Tipo de documento
journal article
Resumen
Objectives: To assess the effectiveness and tolerability of dolutegravir (DTG)/lamivudine (3TC) among treatment-naive and virologically suppressed treatment-experienced individuals in the multicentre cohort of the Spanish HIV/AIDS Research Network (CoRIS) during the years 2018-2021. Methods: We used multivariable regression models to compare viral suppression (VS) [HIV RNA viral load (VL) <50 copies/mL] and the change in CD4 cell counts at 24 and 48 (±12) weeks after initiation with dolutegravir/lamivudine or other first-line ART regimens. Results: We included 2160 treatment-naive subjects, among whom 401 (18.6%) started with dolutegravir/lamivudine. The remaining subjects started bictegravir (BIC)/emtricitabine (FTC)/tenofovir alafenamide (TAF) (n = 949, 43.9%), DTG + FTC/tenofovir disoproxil fumarate (TDF) (n = 282, 13.1%), DTG/3TC/abacavir (ABC) (n = 255, 11.8%), darunavir (DRV)/cobicistat(COBI)/FTC/TAF (n = 147, 6.8%) and elvitegravir (EVG)/COBI/FTC/TAF (n = 126, 5.8%). At 24 and 48 weeks after starting dolutegravir/lamivudine, 91.4% and 93.8% of the subjects, respectively, achieved VS. The probability of achieving VS with dolutegravir/lamivudine was not significantly different compared with any other regimen at 24 or 48 weeks, with the exception of a lower chance of achieving VS at 24 weeks for DRV/COBI/FTC/TAF (adjusted OR: 0.47; 95% CI: 0.30-0.74) compared with dolutegravir/lamivudine.For the analysis of treatment-experienced virally suppressed subjects we included 1456 individuals who switched to dolutegravir/lamivudine, among whom 97.4% and 95.5% maintained VS at 24 and 48 weeks, respectively. During the first 48 weeks after dolutegravir/lamivudine initiation, 1.0% of treatment-naive and 1.5% of treatment-experienced subjects discontinued dolutegravir/lamivudine due to an adverse event. Conclusions: In this large multicentre cohort, effectiveness and tolerability of dolutegravir/lamivudine were high among treatment-naive and treatment-experienced subjects.
MESH
HIV-1 | Anti-HIV Agents | HIV Infections | Humans | Lamivudine | Oxazines | Heterocyclic Compounds, 3-Ring | Pyridones | Emtricitabine
Versión en línea
DOI
Aparece en las colecciones
- Investigación > ISCIII > Centro Nacional de Epidemiología (CNE)
- Investigación > IIS > i+12 - Instituto de Investigación Hospital 12 de Octubre (Madrid)
- Investigación > IIS > ibs.GRANADA - Instituto de Investigación Biosanitaria de Granada (Andalucía)
- Investigación > IIS > IdISSC - Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (Madrid)
- Investigación > IIS > IMIB - Instituto Murciano de Investigación Biosanitaria Pascual Parrilla (Murcia)
- Investigación > IIS > IRYCIS - Instituto Ramón y Cajal de Investigación Sanitaria (Madrid)
Ficheros en el ítem
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- EffectivenessTolerabilityDolut ...
- Tamaño:
- 299.6Kb
- Formato:
- Descripción:
- Articulo
![Acceso Abierto Acceso Abierto](/themes/Mirage2/images/openAccess.png)
- Nombre:
- Supplementary_EffectivenessTol ...
- Tamaño:
- 648.6Kb
- Formato:
- Descripción:
- Supplementary material